EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Camrelizumab Plus Famitinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Study

Bei Xu iD, Guopei Zhu iD, Jin Lu, Ximei Zhang, Xiaozhong Chen, Qinjiang Liu, Song Qu iD, Jia Fan iD, Tianshu Liu

Cancer Medicine · 2026-05 · 15 (5)

DOI: 10.1002/cam4.71899 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, online erschienen am 21.05.2026. Verfasst von Bei Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Head and Neck Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jiangsu Hengrui Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To evaluate the outcomes of patients with refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with camrelizumab combined with famitinib following platinum‐based chemotherapy.

Methods

In this multicenter, phase 2, single‐arm trial, patients with R/M HNSCC who had documented progression after platinum‐based chemotherapy were administered camrelizumab 200 mg every 3 weeks and famitinib at 20 mg once daily (cohort 1). The primary endpoint was the objective response rate (ORR). The key secondary endpoints included progression‐free survival (PFS), duration of response (DOR), time to objective response (TTR), disease control rate (DCR), overall survival (OS), and safety.

Findings

Between August 07, 2020 and June 22, 2022, a total of 20 patients with R/M HNSCC were enrolled. The median age of the patients was 61 years (range, 37–69). The ORR was 35.0% (95% CI, 15.4–59.2) and the DCR was 55.0% (95% CI, 31.5–76.9). The median TTR was 2.23 months (95% CI, 2.0–8.3), the median DOR was 8.0 months (95% CI, 2.2 to not reach), the median PFS was 4.1 months (95% CI, 1.7–10.3), and the median OS was 8.4 months (95% CI, 3.0–17.0), with a median follow‐up duration of 7.2 months (range 0.1 months to 19.6 months). Treatment‐related adverse events (TRAEs) of grade ≥ 3 included decreased white blood cell count (15.0%), hypertension (15.0%), pneumonia (15.0%), and tumor bleeding (15.0%). The most common TRAEs of any grade were decreased white blood cell count (50.0%), anemia (50.0%), hypertension (50.0%), and decreased platelet count (45.0%).

Interpretation

In this single‐arm phase II trial, camrelizumab plus famitinib demonstrated encouraging efficacy and a manageable safety profile in patients with refractory R/M HNSCC. These preliminary findings warrant further investigation. Trial Registration ClinicalTrials.gov identifier: NCT04346381

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHead and Neck NeoplasmsNeoplasm Recurrence, LocalQuinolonesSquamous Cell Carcinoma of Head and NeckAdultAgedFemaleHumansMaleMiddle AgedNeoplasm MetastasisProgression-Free SurvivalIndolesPyrroles

Stichwörter der Autor:innen

CamrelizumabFamitinibPD‐1 inhibitorVEGFRhead and neck squamous cell carcinoma

Substanzen

Antibodies, Monoclonal, HumanizedcamrelizumabfamitinibQuinolonesIndolesPyrroles

Autor:innen und Institutionen

  • Department of Medical Oncology, Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Oral & Maxillofacial-Head & Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Abdominal Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Cancer Hospital Affiliate to School of Medicine, UESTC, Chengdu, China.
  • Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
  • Department of Radiation Oncology, Gansu Provincial Cancer Hospital, Lanzhou, China.

ORCID-Profile: Bei Xu, Guopei Zhu, Song Qu, Jia Fan

Förderung

  • Jiangsu Hengrui Medicine

Zitieren

APA

Xu, B., Zhu, G., Lu, J., Zhang, X., Chen, X., Liu, Q., Qu, S., Fan, J., & Liu, T. (2026). Camrelizumab Plus Famitinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Study. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71899

Vancouver

Xu B, Zhu G, Lu J, Zhang X, Chen X, Liu Q, et al. Camrelizumab Plus Famitinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Study. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71899

BibTeX
@article{Xu2026,
  author = {Xu, Bei and Zhu, Guopei and Lu, Jin and Zhang, Ximei and Chen, Xiaozhong and Liu, Qinjiang and Qu, Song and Fan, Jia and Liu, Tianshu},
  title = {Camrelizumab Plus Famitinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Study},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cam4.71899}
}
Kostenlos starten →